We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Traceability Requirements in EU’s ATMP Regulation Need Tweaking: Pfizer
Traceability Requirements in EU’s ATMP Regulation Need Tweaking: Pfizer
June 12, 2013
Language on traceability requirements in the EU’s 2007 regulation on innovative “advanced therapies” is overly broad and should be clarified in forthcoming guidance, pharma giant Pfizer says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor